Skip to content

Effect of pretreatment with oxytocin nasal spray on postoperative acute stress disorder in patients with accidental fracture

Effect of pretreatment with oxytocin nasal spray on postoperative acute stress disorder in patients with accidental fracture

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082612
Enrollment
Unknown
Registered
2024-04-01
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative stress disorder

Interventions

Control Group:Nasal administration of physiological saline
Oxytocin group:Oxytocin nasal spray 40U

Sponsors

the General Hospital of the Western Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) All fractures were caused by traumatic events (such as car accidents, work-related injuries, etc.) and were first treated in our hospital after the injury; (2) Age range from 18 to 65 years old; (3) The American Society of Anesthesiologists grades I to III; (4) Clear consciousness, normal cognitive ability, able to independently or with the help of researchers understand questionnaires and related scales; (5) The patient fully understands and is willing to participate in this study.

Exclusion criteria

Exclusion criteria: (1) Patients with intellectual disabilities and communication barriers; (2) Central nervous system diseases caused by acute trauma, long-term or intermittent coma, and mental disorders; (3) Pathological fractures; (4) Severe organ dysfunction such as heart, brain, and lungs before fracture; (5) Merge malignant tumors;(6) Taboos for nasal administration (such as lesions or injuries in the nasal cavity); (7) Previously allergic to oxytocin; (8) Pregnant women; (9) Patients with hypertension of grade 2 or above; (10) Patients who are unwilling to participate in this study.

Design outcomes

Primary

MeasureTime frame
SAS-RQ rating;

Secondary

MeasureTime frame
rating;CD-RISC rating;HAD rating;VAS rating;Salivary concentrations of propylene glycol (MDA), cortisol (CORT), and superoxide dismutase (SOD);

Countries

China

Contacts

Public ContactHuang Qingqing

the General Hospital of the Western Theater Command

970327481@qq.com+86 152 8301 7764

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026